CALIFORNIA STI TREATMENT GUIDELINES TABLE FOR ADULTS & ADOLESCENTS

These guidelines reflect the 2021 CDC STI Treatment Guidelines for adults and adolescents who are HIV negative as well as those with HIV. Call the local health department for assistance with confidential notification of sexual partners of patients with STIs or HIV. For complex STI clinical management consultation (such as in cases of multiple allergies or treatment failure), contact the California Department of Public Health STD Control Branch via email (stdcb@cdph.ca.gov) or phone (510-620-3400) or submit your question online to the STD Clinical Consultation Network at www.stdccn.org. An ADA-compliant version of this document is posted online at https://www.cdph.ca.gov/Programs/CID/DCDC/Pages/California-STI-Treatment-Guidelines.aspx.

INFECTION/DISEASE	RECOMMENDED REGIMENS	ALTERNATIVE REGIMENS: To be used if medical contraindication to recommended regimen.
Urogenital/Rectal/Pharyngeal	Doxycycline ¹ 100 mg po bid x 7 d	Azithromycin 1 g po x 1 dose OR
Infections		Levofloxacin 500 mg po once daily x 7 d Amoxicillin 500 mg po tid x 7 d
Pregnant Patients ²	Azithromycin 1 g po x 1 dose	
has not been excluded, add do	otherapy with IM ceftriaxone is recommended for all patients with gonorrhea, inclue oxycycline 100 mg po bid x 7 d for non-pregnant persons or azithromycin 1 g po x 1	ding pregnant patients. If co-infection with chiamydia dose for pregnant persons.
Urogenital/Rectal Infections ³	 Ceftriaxone 500 mg IM x 1 dose for persons weighing <150 kg⁴ OR 	If cephalosporin allergy: dual therapy with
	 Ceftriaxone 1 g IM x 1 dose for persons weighing ≥150 kg 	• Gentamicin ¹ 240 mg IM x 1 dose PLUS
		Azithromycin 2 g po x 1 dose
		If ceftriaxone not available or feasible, but no allergy
		concerns:
		Cefixime 800 mg x 1 dose ⁵
Pharyngeal Infections ^{3,6}	 Ceftriaxone 500 mg IM x 1 dose for persons weighing <150 kg⁴ OR Ceftriaxone 1 g IM x 1 dose for persons weighing >150 kg 	No reliable treatment alternatives. Consult an infectious disease specialist or submit a question
		online at <u>www.stdccn.org</u> .
PELVIC	Parenteral	Parenteral
INFLAMMATORY DISEASE (PID) ⁷	Ceftriaxone 1 g IV q 24 hrs PLUS Doxycycline ¹ 100 mg IV or po q 12 hrs PLUS	 Ampicillin/Sulbactam 3 g IV q 6 hrs PLUS Doxycycline¹ 100 mg po or IV q 12 hrs
(Etiologies: CT, GC, anaerobes,	Metronidazole 500 mg IV or po q 12 hrs OR	OR NOT A REAL PLANE
possibly M. genitalium, others)	Either Cefotetan 2 g IV q 12 h OR Cefoxitin 2 g IV q 6 h	 Clindamycin 900 mg IV q 8 hrs PLUS Gentamicin¹ 2 mg/kg IV or IM x 1 as loading dose
	PLUS Doxycycline ¹ 100 mg po or IV g 12 hrs	FOLLOWED BY
		 Gentamicin¹ 1.5 mg/kg IV or IM q 8 h as maintenand dose (or can substitute with Gentamicin¹ 3-5 mg/kg
	IM/Oral	IM or IV 1x daily)
	• Either Ceftriaxone 500 mg IM x 1 dose ⁴ (or another 3 rd generation cephalosporin ⁸) OR	IM/Oral ⁹
	Cefoxitin 2 g IM x 1 dose administered with Probenecid 1 g po x 1 dose	• Either Levofloxacin 500 mg po daily OR Moxifloxac
	PLUS Doxycycline ¹ 100 mg po bid x 14 d	400 mg po daily, WITH Metronidazole 500 mg po bi x 14 d
	WITH	OR
	Metronidazole 500 mg po bid x 14 d	 Azithromycin 500 mg IV daily x 1-2 doses followed b 250 mg po daily WITH Metronidazole 500 mg po bio
		x 12-14 d
CERVICITIS ¹⁰	Doxycycline ¹ 100 mg po bid x 7 d	Azithromycin 1 g po x 1 dose
(Etiologies: CT, GC, T. vaginalis, HSV, possibly M. genitalium)	,	
NONGONOCOCCAL	Doxycycline ¹ 100 mg po bid x 7 d	Azithromycin 1 g po x 1 dose
URETHRITIS (NGU) ¹⁰		• Azithromycin 500 mg po x 1 dose, then 250 mg po
		daily x 4 d
RECURRENT/	1) Test for <i>M. genitalium (MG)</i>	For settings without MG resistance testing and when
PERSISTENT NGU	If MG test positive but resistance testing unavailable, use:	moxifloxacin cannot be used: • Doxycycline ¹ 100 mg po bid x 7 d PLUS
(Etiolgies: M. genitalium (MG), T.vaginalis, other bacteria)	Doxycycline ¹ 100 mg po bid x 7 d FOLLOWED BY	Azithromycin 1 g po x 1 dose on first day
	Moxifloxacin 400 mg po daily x 7 d	FOLLOWED BY • Azith romycin 500 mg po once daily for 3 d AND
	If MG test positive and resistance testing is available, use: Macrolide sensitive:	Perform a test of cure 21 d after treatment
	Doxycycline ¹ 100 mg po bid x 7 d FOLLOWED BY	
	Azithromycin 1 g po once, then 500 mg daily on next 3 d	
	Macrolide resistant:	
	 Doxycycline¹ 100 mg po bid x 7 d FOLLOWED BY Moxifloxacin 400 mg po daily x 7 d 	
	 2) Test and treat presumptively for <i>T. vaginalis</i> in men who have sex with women (MSW) in areas where infection is prevalent Metronidazole or Tinidazole 2 g po x 1 dose (applies to both medications) 	
PROCTITIS: (Etiologies:	Ceftriaxone 500 mg IM x 1 dose for persons weighing <150 kg ⁴ OR	• None
GC, CT including LGV, HSV, T.	Ceftriaxone 1 g IM x 1 dose for persons weighing ≥150 kg PLUS	
pallidum, possibly M. genitalium);	Doxycycline ¹ 100 mg po bid x 7 d ¹¹	
LYMPHOGRANULOMA	Doxycycline ¹ 100 mg po bid x 21 d	Azithromycin 1 g po once weekly x 3 weeks ¹²
VENEREUM (LGV)		OR
		Erythromycin base 500 mg po qid x 21 d
	TE: Treatment recommendations do not vary by HIV status.	
Cervicovaginal infection	Metronidazole 500 mg po bid x 7 d	 Tinidazole¹⁴ 2 g po x 1 dose OR Secnidazole¹⁵ 2 g po x 1 dose
Penile infection	Metronidazole 2 g po x 1 dose	

¹ Contraindicated for pregnant patients.

² Every effort should be made to use a recommended regimen. Test-of-cure follow-up with a nucleic acid amplification test (NAAT) 4 weeks after completion of therapy is recommended in pregnancy. ³ See Gonorrhea Treatment Guidelines and Management of Suspected Treatment Failure

(https://www.cdph.ca.gov/Programs/CID/DCDC/CDPH%20Document%20Library/CAGCTreatmentFailureProtocol_Providers.pdf) if suspected GC treatment failure.


⁴ For persons weighing ≥150 kg, use 1 gm IM ceftriaxone x 1 dose instead.
 ⁵ Oral cephalosporins give lower and less-sustained bactericidal levels than ceftriaxone. Cefixime should only be used when ceftriaxone is not available.
 ⁶ Test of cure by culture or NAAT is recommended 14 days after treatment of pharyngeal GC.
 ⁷ If parenteral therapy is selected initially, discontinue 24-48 hours after patient improves clinically and continue with either IM or oral therapy for a total of 14 days.
 ⁸ Other parenteral third-generation cephalosporin (e.g. cefotaxime or ceftizoxime) could be substituted for ceftriaxone.
 ⁹ If allergy to cephalosporins, can consider fluoroquinolones/azithromycin tor PID treatment if community prevalence and individual risk of GC is low, and follow-up is assured. Obtain NAAT testing and CC on therapy is assured. Obtain NAAT

testing and GC culture before using fluoroquinolone/azithromycin treatment. ¹⁰ If patient lives in community with high GC prevalence, or has risk factors (e.g. age <25 years, new partner, partner with concurrent sex partners, or sex partner with a STI), consider empiric treatment for GC.

¹¹ Extend doxycycline course to 21 days to cover LGV if perianal or mucosal ulcers, bloody rectal discharge, or tenesmus and rectal CT positive. If perianal or mucosal ulcers present, consider treating for HSV as well.

¹² Because this regimen has not been rigorously validated, consider a test of cure with CT NAAT four weeks after treatment.
 ¹³ For suspected drug-resistant trichomoniasis consult the 2021 CDC STI treatment guidelines, contact the CA STD Control Branch, or consult www.stdccn.org.

 ¹⁴ Safety in pregnancy has not been established, avoid during pregnancy. When using tinidazole, breastfeeding should be deferred for 72 hours after 2 g dose.
 ¹⁵ Sprinkle oral granules on applesauce/yogurt/pudding before ingestion. Glass of water after dose can aid in swallowing. FDA-approved for treatment of trichomonas after the release of the CDC's 2021 STI Treatment Guidelines. California Department of Public Health STD Control Branch



California Prevention & Training Center Submit a question online at www.stdccn.org Version date: November 2021



INFECTION/DISEASE	RECOMMENDED REGIMENS	ALTERNATIVE REGIMENS: To be used medical contraindication to recommended regimen.
BACTERIAL VAGINOSIS	 Metronidazole 500 mg po bid x 7 d OR Metronidazole gel 0.75% one full applicator (5 g) intravaginally once daily x 5 d OR Clindamycin cream 2% one full applicator (5 g) intravaginally qhs x 7 d 	 Tinidazole¹⁴ 2 g po daily x 2 d OR Tinidazole¹⁴ 1 g po daily x 5 d OR Secnidazole¹⁵ 2 g po x 1 dose OR Clindamycin 300 mg po bid x 7 d OR Clindamycin ovules¹⁶ 100mg intravaginally qhs x 3 d
EPIDIDYMITIS	If likely due to GC or CT Ceftriaxone 500 mg IM x 1 dose⁴ PLUS Doxycycline 100 mg po bid x 10 d 	• None
	If likely due to GC, CT or enteric organisms (history of insertive anal sex) Ceftriaxone 500 mg IM x 1 dose⁴ PLUS Levofloxacin 500 mg po daily x 10 d 	
	If most likely due to enteric organisms alone (GC and CT tests negative) Levofloxacin¹⁷ 500 mg po daily x 10 d 	
ANOGENITAL WARTS		
External Genital/Perianal Warts	Patient-Applied Imiquimod ^{18,19} 5% cream topically qhs 3x/wk up to 16 wks OR Imiquimod ^{18,19} 3.75% cream topically qhs for up to 8 wks OR Podofilox 0.5% solution or gel topically bid x 3 d then 4 d off, repeat up to 4 cycles OR Sinecatechins ¹⁸ 15% ointment topically tid for up to 16 wks Provider-Administered Cryotherapy with liquid nitrogen, apply once q1-2 wks OR Trichloroacetic acid (TCA) 80%-90%, apply once q 1-2 wks OR Bichloroacetic acid (BCA) 80%-90%, apply once q 1-2 wks OR	Alternative Regimen – (fewer data available) Provider Administered • Podophyllin resin ²⁰ 10-25% in tincture of benzoin, applied weekly PRN OR • Intralesional interferon OR • Photodynamic therapy OR • Topical cidofovir
Mucosal Genital Warts	Surgical removal Urethral meatus, Vaginal, Cervical, Intra-Anal Cryotherapy ²¹ with liquid nitrogen OR Surgical removal OR	• None
	Vaginal, Cervical, Intra-anal TCA or BCA 80-90% 	
ANOGENITAL HERPES		
First Clinical Episode of Herpes ²²	 Acyclovir 400 mg po tid x 7-10 d OR Valacyclovir 1 g po bid x 7-10 d OR Famciclovir 250 mg po tid x 7-10 d 	• None
Daily Suppressive Therapy for Recurrences (if no HIV co- infection)	 Acyclovir 400 mg po bid OR Valacyclovir 500 mg po daily²³ OR Valacyclovir 1 g po daily OR Famciclovir²⁴ 250 mg po bid 	
Daily Suppressive Therapy in Pregnant Patients (start at 36 weeks gestation)	 Acyclovir 400 mg po tid OR Valacyclovir 500 mg po bid 	
Episodic Therapy for Recurrences (If no HIV co- infection)	 Acyclovir 800 mg po bid x 5 d OR Acyclovir 800 mg po tid x 2 d OR Valacyclovir 500 mg po bid x 3 d OR Valacyclovir 1 g po daily x 5 d OR Famciclovir 1 gm po bid x 1 d OR Famciclovir 500 mg po once, then 250 mg po bid x 2 d OR Famciclovir 125 mg po bid x 5 d 	
Persons with HIV ²⁵		
Daily Suppressive Therapy	 Acyclovir 400-800 mg po 2-3 times daily OR Valacyclovir 500 mg po bid OR Famciclovir²⁴ 500 mg po bid 	• None
Episodic Therapy for Recurrences	 Acyclovir 400 mg po tid x 5-10 d OR Valacyclovir 1 gm po bid x 5-10 d OR Famciclovir 500 mg po bid x 5-10 d 	
SYPHILIS ²⁶ NOTE: Treatmen	nt recommendations do not vary by HIV status.	
Primary, Secondary, and Early Latent	Benzathine penicillin G 2.4 million units IM x 1 dose	 Doxycycline²⁷ 100 mg po bid x 14 d OR Tetracycline²⁷ 500 mg po qid x 14 d OR Ceftriaxone²⁷ 1 g IM or IV daily x 10-14 d
Late Latent or Syphilis of Unknown Duration OR Tertiary Syphilis with normal CSF	 Benzathine penicillin G 7.2 million units total, administered as 3 doses of 2.4 million units IM each at 1 week intervals²⁸ 	Doxycycline ²⁷ 100 mg po bid x 28 d OR Tetracycline ²⁷ 500 mg po qid x 28 d
Neurosyphilis and Ocular Syphilis ²⁹	 Aqueous crystalline penicillin G 18-24 million units daily, administered as 3-4 million units IV q 4 hrs or as continuous infusion x 10-14 d 	 Procaine penicillin G 2.4 million units IM daily x 10-14 d PLUS Probenecid 500 mg po qid x 10-14 d OR, in the setting of severe penicillin allergy Ceftriaxone²⁷ 1-2 gm IM or IV daily x 10-14 d
Pregnant Patients ³⁰ NOTE: Pre Primary, Secondary, and Early Latent	 gnant patients who miss any dose of therapy must repeat full course of treatment. Benzathine penicillin G 2.4 million units IM x 1 dose³¹ 	• None
Late Latent or Syphilis of Unknown Duration OR Tertiary Syphilis with normal CSF	 Benzathine penicillin G 7.2 million units total, administered as 3 doses of 2.4 million units IM each, at 1-week intervals³² 	• None
Neurosyphilis and Ocular Syphilis ²⁹	 Aqueous crystalline penicillin G 18-24 million units daily, administered as 3-4 million units IV q 4 hrs or as continuous infusion x 10-14 d 	 Procaine penicillin G 2.4 million units IM daily x 10-14 d PLUS Probenecid 500 mg po gid x 10-14 d

¹⁶ Clindamycin ovules may weaken latex or rubber products (such as condoms and diaphragms). Use of such products within 72 hours following use of clindamycin ovules is not recommended.

¹⁷ Gonorrhee should be ruled out prior to starting a fluroquinolone-based regimen.
 ¹⁸ May weaken condoms and vaginal diaphragms. Advise patients to follow package insert directions carefully. Imiquimod users was h area 6-10 hours after application. Sinecatechin ointment should not be washed off.

²⁰ Finited human data on imiquimod use in pregnancy; animal data suggest low risk. ²⁰ Podophyllin resin is an alternative rather than recommended regimen **due to reports of severe toxicity**. The safety of podophyllin in pregnancy has not been established.

²⁰ Podophyllin resin is an alternative rather than recommended regimen due to reports of severe toxicity. The safety of podophyllin in pregnancy has not been establis
 ²¹ The use of a cryoprobe in the vagina is not advised due to risk of vaginal perforation and fistula formation.
 ²² Treatment can be extended if healing is incomplete after 10 days of antiviral therapy.
 ²³ Consider high dose valacyclovir (1 gm daily) or acyclovir in people who have frequent recurrences (i.e., 10 or more episodes annually).
 ²⁴ Famciclovir is somewhat less effective for suppression of viral shedding.
 ²⁵ If concern for resistance based on persistent HSV lesions, obtain a viral isolate for sensitivity testing. Consultation with an infectious disease expert is recommended.
 ²⁶ Renarching applicible. G is only one long acting formulation formulation a plauline.

²⁵ If concern for resistance based on persistent HSV lesions, obtain a viral isolate for sensitivity testing. Consultation with an infectious disease experts recommended.
 ²⁶ Benzathine penicillin G is available in only one long-acting formulation, Bicillin® L-A (the trade name), which contains only benzathine penicillin G. Other combination products, such as Bicillin® C-R, contain both long- and short-acting penicillins and are not effective for treating syphilis.
 ²⁷ Alternative regimens should be used only for penicillin-allergic patients. If compliance or follow-up cannot be ensured, the patient should be desensitized and treated with benzathine combination.

²⁸ In non-pregnant patients, pharmacologic considerations reveal an interval of 7-9 days is ideal.

⁴⁴ In non-pregnant patients, pharmacologic considerations reveal an interval of 7-9 days is local.
 ²⁹ Some specialists recommend 2.4 million units of benzathine penicillin G once weekly for 1 to 3 weeks immediately after completion of neurosyphilis treatment.
 ³⁰ Pregnant patients allergic to penicillin should be desensitized and treated with penicillin. There are no alternatives.
 ³¹ For early syphilis, many experts give a 2nd dose of benzathine penicillin G 2.4 million units IM one week after the initial dose.
 ³² The optimal treatment interval in pregnancy is 7 days. If treatment occurs outside of 6–8-day intervals, the full treatment course should be restarted.



California Department of Public Health STD Control Branch Phone: 510-620-3400; email: stdcb@cdph.ca.gov

California Prevention & Training Center Submit a question online at www.stdccn.org Version date: November 2021

